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pjia@sjtu.edu.cnAbstract Berberine from Rhizoma Coptidis is an oral hypoglycemic agent with anti-dyslipidemia
and anti-obesity activities. Its metabolic activity of regulating blood glucose and lipids has been
widely studied and evidenced in patients and various animal models. Berberine is known as an
AMP-activated protein kinase (AMPK) activator. Its insulin-independent hypoglycemic effect is
related to inhibition of mitochondrial function, stimulation of glycolysis and activation of AMPK
pathway. Additionally, berberine may also act as an a-glucosidase inhibitor. In the newly-
diagnosed type 2 diabetic patients, berberine is able to lower blood insulin level via enhancing
insulin sensitivity. However, in patients with poor b-cell function, berberine may improve insulin
secretion via resuscitating exhausted islets. Furthermore, berberine may have extra beneﬁcial effects
on diabetic cardiovascular complications due to its cholesterol-lowering, anti-arrhythmias and
nitric oxide (NO) inducing properties. The antioxidant and aldose reductase inhibitory activities of
berberine may be useful in alleviating diabetic nephropathy. Although evidence from animal and
human studies consistently supports the therapeutic activities of berberine, large-scale multicenter
trials are still necessary to evaluate the efﬁcacy of berberine on diabetes and its related
complications.
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Berberine is the major active component of Rhizoma Coptidis,
a popular traditional Chinese herb in the treatment of diabetes
and inﬂammation. The content of berberine in Rhizoma
Coptidis is 5.2–7.7%. Rhizoma Coptidis is made from several
plants including Coptis chinensis French, Coptis deltoidea C.
Y. Cheng et Hsiao and Coptis teetoides C. Y. Cheng. The
earliest record of Rhizoma Coptidis as a medicinal herb was in
A.D. 200 in The Herbal Classic of the Divine Plowman (Shen
Nong Ben Cao Jing). In about A.D. 500, the anti-diabetes
activity of Rhizoma Coptidis was recorded for the ﬁrst time in
a book titled ‘‘Note of Elite Physicians’’. However, in most
ancient books, the major therapeutic activity of Rhizoma
Coptidis is considered as anti-infection or anti-inﬂammation
because infectious diseases were much more popular than
diabetes in ancient time1,2.
Although the Chinese name of berberine, Huangliansu,
means element of Rhizoma Coptidis, most berberine used in
medical practice are not extracted from this herb because of
high cost. Usually, it is prepared from other herbs such as
Berberis amurense Rupr. and Phellodendron amurense Rupr.
Among many chemical forms of berberine, i.e., berberine
hydrochloride, berberine sulfate, berberine citrate or phos-
phate2, berberine hydrochloride is the most common form.
The antimicrobial activity of berberine is well-established in
treatment of infection caused by bacteria, viruses, fungi,
protozoans and helminthes. In China, berberine is an over-
the-counter drug for the treatment of bacterial diarrhea. In
1988, the hypoglycemic effect of berberine was ﬁrstly reported
when berberine was prescribed to treat diarrhea in diabetic
patients3. Since then, berberine has been used as an anti-
diabetic agent in folk medicine of China.2. Efﬁcacy of berberine on diabetic patients
Numerous clinical reports about the hypoglycemic action of
berberine can be found in Chinese literatures. Berberine was
claimed to have a comparable activity to sulphonureas or
metformin in reducing blood glucose, although most of the
studies were not well designed. Up to now, berberine has been
tested in several clinical trials. Our study conﬁrmed that
administration of berberine (0.5 g t.i.d.) at the beginning of
each meals was able to reduce fasting blood glucose (FBG)
and postprandial blood glucose (PBG) in patients with newly-
diagnosed type 2 diabetes4. Hemoglobin A1c (HbA1c) levels
were dropped by 2.0%, which is comparable to the effect of
metformin. In poorly-controlled diabetic patients with insulin
injection, berberine reduced HbA1c by 0.8%. In addition to
the hypoglycemic action, plasma triglycerides, total cholesterol
and low-density lipoprotein (LDL) were decreased with
berberine treatment, too4,5. The similar results were also
reported by another group6. In this two-center, randomized,
double-blind trial, HbA1c decreased by 0.9% after berberine
(0.5 g b.i.d.) treatment. All parameters including blood glucose
and lipids were improved signiﬁcantly. In short-term clinical
trials, only minor gastrointestinal adverse events, such as
constipation, ﬂatulence and diarrhea, were observed. In our
study, no signiﬁcant changes of plasma alanine aminotrans-
ferase (ALT), g-glutamyl transpeptidase (g-GT), and creati-
nine were observed. In another study, serum ALT, aspartateaminotransaminase (AST) and g-GT were signiﬁcantly
reduced in the berberine group. This indicates berberine has
no liver or kidney toxicity at the dose given in above studies.
Although hypoglycemic effect of berberine was reported in
mounting Chinese literature evidence, large scale, long-term
clinical trial are still needed to evaluate the efﬁcacy of
berberine in the treatment of diabetes.3. Berberine on glucose metabolism in animals
Berberine was shown to decrease blood glucose, enhance
insulin sensitivity and reduce weight gain in both dietary
and genetic rodent models of type 2 diabetes. In high-fat diet
induced obese rats, berberine decreased FBG, PBG, fasting
insulin, homeostasis model of assessment-insulin resistance
(HOMA-IR) and body weight4,7,8. In low dose of streptozo-
tocin (STZ) and high-fat diet induced type 2 diabetic rats,
berberine treatment signiﬁcantly decreased FBG and
improved insulin tolerance8,9. In leptin receptor-deﬁcient
db/db mice, glucose tolerance was improved and body weight
was reduced with berberine7. In alloxan-induced type 1
diabetic rats, berberine also restored the injured pancreas10.4. Berberine and islet function
Impacts of berberine on islet are controversial. Our previous
work showed that berberine had no insulin secretagogue
effects on b-TC3 cells in vitro11. Berberine restored pancreatic
islet hyperthophy back to normal. Our clinical trial showed
that berberine lowered fasting insulin levels in the newly
diagnosed type 2 diabetic patients. However, in the poorly-
controlled diabetic patients with insulin injection, berberine
did raise the fasting and postprandial C-peptide levels4. The
data suggest although berberine did not stimulate the insulin
secretion directly, it may be able to improve the islet function
in patients unresponsive to oral hypoglycemic agents. Dr.
Zhou’s work12 indicated that berberine reduced plasma insulin
levels in high-fat diet fed rats and blunted insulin secretion in
MIN6 b-cells and isolated rat islets directly. However, other
groups reported that berberine decreased blood glucose via
islet protection in Nonobese diabetic (NOD) mice—a sponta-
neous type 1 diabetic model13,14. The effects of increasing islet
numbers and blood insulin levels were not observed in
berberine treated db/db mice. Thus, these results indicate
berberine may have a two-way regulation in pancreas islets.
In typical type 2 diabetes with notable insulin resistance,
berberine lowered blood insulin level through increasing
insulin sensitivity. However, in type 1 diabetes or the late
stage of type 2 diabetes characterized by poor b-cell function,
berberine was able to increase insulin secretion via repairing
destructed or exhausted islets, which may be related to its
antioxidant and anti-lipid peroxidation properties15.5. Berberine on lipid metabolism
Berberine was reported to improve lipid metabolism in both
animals and human subjects. Two clinical trials showed that
berberine decreased triglycerides by 35% and 22%, serum
cholesterol by 29% and 16%, and LDL-C by 25% and 20% in
patients with dyslipidemia5,16. In high-fat diet induced obese
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more, triglycerides deposition in muscle and liver was reduced
signiﬁcantly, and liver steatosis was prevented with berberine
administration8,17. In hamster or diabetic rats fed with
high-cholesterol diet, berberine was reported to decrease
triglycerides, serum cholesterol and LDL-C signiﬁcantly5,10,18,
although berberine seems to have little effects on high-density
lipoprotein (HDL) level5,16. In addition, berberine reduced
levels of serum free fatty acids (FFA) in normal lean rats8,9.
Reduction of cholesterol with berberine is related to the
induction of LDL receptor (LDLR) expression in liver, which
may be due to extended half-life of LDLR mRNA via
activation of extracellular signal-regulated kinases (ERK) by
berberine5,19. Since ERK activation was not observed in other
type of cells, the activity of berberine may be hepatocyte
speciﬁc4,20,21. One study showed that the effect of berberine on
LDLR was blocked by a c-Jun N-terminal kinase (JNK)
inhibitor. Activation of JNK by berberine may be involved in
the induction of LDLR22.6. Insulin-independent effects of berberine in vitro
In the ﬁrst in vitro study using hepatocytes (HepG2 cell line),
berberine was shown to stimulate glucose consumption in an
insulin-independent manner, and the activity was similar to that
of metformin11. Several studies conﬁrmed the insulin-indepen-
dent activity of berberine in other cell models e.g., muscle cells
(L6 and C2C12 cell lines) and adipocytes (3T3-L1 cell line)7,23–28.
In the presence of insulin, berberine exhibited synergetic effect on
insulin-induced glucose consumption and glucose uptake. Since
berberine stimulated glucose uptake markedly, it is of interest
whether the effect is attributed to the regulation of glucose
transporters. Berberine was shown to induce glucose transporter
type 4 (GLUT4) translocation or elevate GLUT4 protein level in
some studies7,28,29, while others failed to conﬁrm that24,26. It is
reported that berberine enhanced glucose transporter 1 (GLUT1)
expression and promoted GLUT1 activities24,30. However, the
effects were not consistent25,26. Our study suggests that regula-
tion of GLUTs may not be the major mechanism involved in
glucose-lowering effect of berberine, which is evidenced by that
the effect of berberine on the translocation or expression of
glucose transporters is only detectable with high concentration of
berberine (Z10 mM)25.7. Berberine activates AMPK
Berberine is characterized as an AMP-activated protein kinase
(AMPK) activator. AMPK is a key energy-sensing/signaling
system in the cells and acts as a fuel gauge by monitoring
cellular energy levels, e.g., AMP/ATP ratio31. Activation of
AMPK is well known to increase insulin sensitivity and
regulate mitochondrial function32. Phosphorylation of Thr-
172 within the catalytic domain of the a subunit (AMPKa) is
necessary for AMPK activity. Various studies demonstrate
that berberine is a strong inducer for Thr-172 phosphorylation
of AMPK7,18,23–25. Our data showed that the AMPK phos-
phorylation was increased at 0.5 h after exposure to berberine
and the increase was maintained for at least 16 h in cells25.
AMPK is formed by a, b, and g subunits, and the a subunit
can exist as either the a1 or a2 isoform. In skeletal muscle,berberine acutely stimulated both AMPKa1 and AMPKa2
with a reduction of the intracellular energy status33. Liver
kinase B1 (LKB1) and Ca2þcalmodulin-dependent kinase II
(CaMKK II) are two major upstream kinases for AMPK
activation. Interestingly, berberine not only stimulated AMPK
(Thr172) phosphorylation, but also induced LKB1 (Ser428)
and CaMKK II (Thr286) phosphorylation34. However, in
LKB1/ cells with or without the CaMKK inhibitor STO-
609, AMPK activation by berberine was not affected. This
suggested the effect of berberine on AMPK is independent of
either LKB1 or CaMKKb35. Berberine was shown to protect
against endothelial injury, enhance the endothelium-depen-
dent vasodilatation, and downregulate proinﬂammatory
responses through activation of the AMPK signaling
cascade34,36,37.8. Berberine inhibits mitochondrial function
Berberine may activate AMPK through increasing AMP/ATP
ratio, which is mediated by inhibition of ATP biosynthesis in
mitochondria23,25. As early as 20 years ago, scientists observed
that berberine inhibited NAD-linked respiration in isolated
mitochondria of rat liver in vitro38,39, which was conﬁrmed by
later studies40. In the mitochondria, berberine inhibited mono-
amine oxidase directly41–43. Our study demonstrated that berber-
ine also inhibited mitochondrial function in living cells25. We
observed that oxygen consumption was decreased and glycolysis
was enhanced with berberine as indicated by increased lactate
production. This alteration is responsible for the upregulated
AMP/ATP ratio. Thus, we hypothesized that AMPK activation
may be a consequence of mitochondrial inhibition by berberine25.
The results also indicate that modest inhibition of mitochondrial
function may contribute to improvement of glucose metabolism.
This is supported by the fact that inhibition of oxidative
phosphorylation protected mice from diet-induced insulin resis-
tance, obesity and type 2 diabetes44. Recently, one group reported
that berberine suppressed respiration in L6 myotubes and isolated
muscle mitochondria, through an inhibitory effect on electron
transporter chain complex I, similar to that observed with
metformin and rosiglitazone35,45.
Mitochondria are the major apparatuses for ATP produc-
tion through oxidative phosphorylation. ATP is required for
nearly all metabolic processes including gluconeogenesis,
adipogenesis, cholesterol and extracellular matrix syntheses.
Various effects of berberine, such as reduction of above
metabolic processes, may be related to its inhibitory effect
on mitochondrial function. Furthermore, complex I of elec-
tron transport chain, the major place of superoxide produc-
tion46, is the target of berberine35,45. Antioxidant activity of
berberine may directly result from complex I inhibition.
Mitochondrial inhibition may play a key role in the activities
of berberine such as preventing fatty liver, reducing blood
glucose and decreasing blood lipids. The details of the
regulation remain to be explored.9. Berberine inhibits mitogen-activated protein kinases
(MAPK)
MAPK signaling pathway is shown to be involved in diabetic
nephropathy via inducing extracellular matrix. In rat glomerular
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ﬁbronectin protein expression and collagen synthesis were
reversed after berberine treatment. This was at least partly
mediated by inhibitory effect of berberine on phospho-
p38MAPK and phospho-CREB47. In RAW264.7 macrophages,
berberine was also reported to suppress the phosphorylation of
MAPKs, such as p38, ERK, and JNK, and the level of reactive
oxygen species37. It is known that type 1 diabetes is resulted from
autoimmune disorders. Berberine prevented the progression of
type 1 diabetes in half of the NOD mice and suppressed Th17
and Th1 differentiation, which was associated with downregulat-
ing of signal transducer and activator of transcription 1 (STAT1)
and signal transducer and activator of transcription 4 (STAT4)
activities through the inhibition of p38 MAPK and JNK
activation48.10. Effects of berberine in gut
It is interesting that berberine also acts as an a-glucosidase
inhibitor. a-Glucosidase is an intestinal enzyme that breaks
down carbohydrates into monosaccharides. Inhibition of the
enzyme will lead to diminished absorption of dietary carbohy-
drates. One group reported that berberine was hardly
absorbed in rat intestine. Sucrase and maltase activities were
inhibited by berberine49. Berberine also effectively inhibited
the activity of disaccharidases in Caco-2 cells50. The results
were conﬁrmed by other groups. Berberine signiﬁcantly
decreased the disaccharidase activities and sucrase-isomaltase
(SI) complex mRNA expression both in STZ-induced diabetic
rats and normal rats51,52. In addition to the a-glucosidase
inhibitory activity, berberine has signiﬁcant antimicrobial
activity via inhibiting the assembly function of FtsZ and
halting the bacteria cell division in the gastrointestinal tract53.
Berberine was able to completely antagonize the tumor
necrosis factor-a (TNFa)-mediated barrier defects in HT-29/
B6 human colon monolayers and in rat colon54. The antibiotic
activity and protection of tight junction barrier may partially
contribute to the anti-diabetic effect of berberine.11. Effect of berberine in liver
Since liver plays a central role in glucose metabolism,
numerous studies focused on effects of berberine especially
in fatty liver disease. In newly diagnosed type 2 diabetics with
nonalcoholic fatty liver disease as a comorbidity, berberine
obviously ameliorated liver steatosis in ultrasonic images,
decreased AST and ALT, reduced hemorheology indicators,
and improved lipids proﬁle55. Similar results were obtained in
another study. Berberine lowered FBG effectively in chronic
hepatitis B and hepatitis C patients with T2DM or impaired
fasting glucose. Liver function was improved greatly in these
patients as indicated by the reduction of liver enzymes56. Our
data showed that hepatic steatosis was alleviated by berberine
through inhibition of fatty acid synthase (FAS) expression.
Berberine decreased fasting blood glucose by direct inhibition
of gluconeogenic genes, phosphoenolpyruvate carboxykinase
(PEPCK) and glucose-6-phosphatase (G6Pase) in liver. The
activities of transcription factors involved in gluconeogenesis,
lipid and cholesterol syntheses, such as Forkhead transcription
factor O1 (FoxO1), sterol regulatory element-binding protein1c (SREBP1) and carbohydrate responsive element-binding
protein (ChREBP), were decreased with berberine, too57.
Other studies showed that in obese and diabetic rodent models,
berberine treatment reduced liver weight, hepatic and plasma
triglycerides, and cholesterol contents58,59. The effects may be
due to upregulated liver X receptor a (LXRa), peroxisome
proliferator-activated receptor a/d (PPARa/d) expression and
downregulated PPARg expression in the liver59,60. In mouse
primary hepatocytes, berberine enhanced hepatocyte nuclear
factor 4 a (HNF4a) expression and induced the activity of
hepatic glucokinase. The effects were not observed in metformin
treated hepatocytes61.12. Berberine and adipogenesis
Our data showed that berberine reduced waist circumference
and waist/hip ratio signiﬁcantly in the absence of weight
change. Similar results were also reported by other groups.
It was indicated berberine may inhibit visceral fat accumulation.
In diabetic rats, adipocyte size and the ratio of white adipose
tissue to body weight were decreased, and adipocyte number was
increased with berberine treatment62. In addition, berberine
derivatives also counteracted the increased adiposity and tissue
triglyceride accumulation in high-fat-fed rodents35,45. Although
berberine was shown to suppress fat accumulation, the current
evidence on mechanisms is controversial. In vitro experiments
showed that berberine inhibited adipocyte differentiation and
reduced lipid accumulation in 3T3-L1 adipocytes, which may be
due to downregulation of several lipogenic genes including
PPARg, C/EBPa, SREBP-1c, fatty acid synthase, acetyl-CoA
carboxylase, acyl-CoA synthase, lipoprotein lipase, aP2 and
CD367,27,63–65. Because most lipogenic genes are down-stream
target of PPARg and C/EBPa, suppression of the two genes is
considered as the key mechanism for inhibition of adipogenesis
by berberine. In contrast, berberine upregulated PPARa/d/g liver
X receptors (LXRs), CDK9 and cyclin T1 expression in white
adipose tissue of type 2 diabetic rodents, although it decreased
signiﬁcantly SREBPs expression62,66. The difference between
in vivo and in vitro results may be due to the concentration of
berberine. At high concentration, berberine directly inhibits
PPARg activity in adipocytes, whereas it shows an opposite
effect at a low concentration in vivo study.13. Effects of berberine on muscle atrophy
Muscle atrophy is a characteristic of chronic diseases including
diabetes. Surprisingly, berberine was reported to promote
muscle atrophy in both wild-type and db/db mice through
hampering mitochondrial function and stimulating the expres-
sion of atrogin-1, which promoted protein degradation and
suppressed protein synthesis67. However, in another study,
berberine improved muscle atrophy, increased glycogen sto-
rage and decreased triglycerides content in skeletal muscle of
type 2 diabetic rats. Further experiments revealed that reduced
expression of CDK9 and cyclin T1 in the muscle was reversed
with berberine68. Berberine also increased PPARa/d expres-
sion and reduced PPARg expression in skeletal muscle similar
as rosiglitazone or fenoﬁbrate69. The controversial data may
be due to diverse methods of administration. Muscle atrophy
was induced by berberine injection. Oral administration of
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effects of berberine remain to be explored.14. Berberine protects cardiovascular system
A growing body of literatures indicated that berberine had
beneﬁcial effects on cardiovascular diseases. In STZ-induced
diabetic rats, ischemia-induced arrhythmias, prolonged QTc
interval and diminished I(to) and I(Ca) current densities were
markedly improved with berberine treatment70. Another study
showed that berberine recovered arrhythmia scores, resting
membrane potential, Kir2.1, I(K1) current and current density
in rats with myocardial infarctionin the presence or absence of
type 2 diabetes71. In both cultured endothelial cells and aorta
isolated from rat, berberine enhanced phosphorylation of
endothelial nitric oxide synthase (eNOS) and promoted the
association of eNOS with heat shock protein 90 (HSP90),
leading to an increased production of nitric oxide (NO)36.
Berberine also improved endothelium-dependent vasorelaxa-
tion via inducing NO, which was due to signiﬁcantly increased
eNOS and decreased NADPH oxidase (NOX4) expression72.
The results suggest that berberine may improve diabetic
cardiovascular complications through restoring endothelial
function.Figure 1 Therapeutic effects of berberine in vivo. In medical
practice, berberine has been applied to treatment of type 2
diabetes, dyslipidemia, fatty liver disease and cardiovascular
diseases. Berberine is also shown to alleviate diabetic nephropathy
in animal experiments.15. Antioxidant and aldose reductase inhibitory activities of
berberine
Oxidative stress and aldose reductase activities are closely
related to diabetic complications. Several groups have explored
obvious beneﬁcial effect of berberine in this ﬁeld. In STZ and
high-carbohydrate/high-fat diet induced diabetic rats with
hyperlipidemia, berberine markedly decreased malondialde-
hyde level and increased catalase, superoxide dismutase,
glutathione peroxidase, and glutathione activities73. Berberine
also improved cognitive performance, lowered hyperglycemia,
oxidative stress, and choline esterase activity in diabetic rats74.
Although most papers indicated that berberine had antioxidant
activity, one group reported that berberine did not affect the
state of oxidative stress in the liver of a high-fat diet- and STZ-
induced diabetic rat model75. Thus, effects of berberine on
antioxidant remain to be elucidated.
Diabetic nephropathy is a representative microvascular
complication of diabetes. Several studies indicated that ber-
berine had an obviously beneﬁcial effect on the complication.
In STZ-induced diabetic rats, fasting blood glucose, blood
urea nitrogen, creatinine, and urine protein over 24 h were
signiﬁcantly decreased, which may be ascribed to the inhibi-
tion of aldose reductase (AR) in mesangium, reduction of
oxidative stress, and regulation of extracellular matrix synth-
esis and cell proliferation76,77. In alloxan-induced diabetic
mice, berberine inhibited the increases in fasting blood
glucose, kidney/body weight ratio, blood urea nitrogen, serum
creatinine and 24-h albuminuria, and prevented renal hyper-
trophy, transforming growth factor beta 1(TGF-b1) synthesis,
ﬁbronectin and type IV collagen (Col IV) accumulation.
Inhibitory effect of berberine on the activation of sphingosine
kinase- sphingosine 1-phosphate (SphK-S1P) signaling path-
way maybe involved in its renoprotective effects78. In vitroexperiments demonstrated that berberine was able to inhibit
the activity of AR directly79.16. Berberine derivatives
The bioavailability of berberine is quite low, therefore, investiga-
tors are engaged in the research to improve the bioavailability
through using its derivatives or novel delivering system. One group
synthesized two berberine derivatives e.g., dihydroberberine
(dhBBR) and 8,8-dimethyldihydroberberine (Di–Me). Similar to
berberine, both inhibited mitochondrial respiration, activated
AMPK and stimulated glucose uptake in vitro. In diet-induced
obese mice, dhBBR and Di–Me counteracted the increased
adiposity, tissue triglyceride accumulation and insulin resistance.
The highest bioavailability and bioactivity were observed for Di–
Me, followed in descending order by dhBBR and berberine35,45.
Another group developed an anhydrous reverse micelle (ARM)
delivery system for berberine administration. Compared to ber-
berine solutions, 2.4-fold enhancement of the oral bioavailability
and 2.1-fold of maximum blood concentration of berberine were
observed in berberine-loaded ARMs treated mice. Therefore,
hypoglycemic effects of berberine were markedly improved with
the new delivery system80.17. Conclusions
Berberine, a single compound identiﬁed from Rhizoma Cop-
tidis, is a promising oral hypoglycemic agent. The metabolic
activity in regulating blood glucose and lipids has been widely
studied and evidenced in patients and various animal models
(Fig. 1). The major mechanism is related to inhibition of
mitochondrial function, stimulation of glycolysis and activa-
tion of AMPK pathway (Fig. 2). Additionally, berberine may
also act as an a-glucosidase inhibitor. In the newly-diagnosed
type 2 diabetic patients, berberine is able to lower blood
Figure 2 Mechanism of berberine in regulation of metabolism: (1) Berberine enhances glucose uptake through induction of glycolysis,
which is due to inhibition of aerobic respiratory. AMPK activation is a consequence of inhibition of mitochondrial electron transport
chain complex I; (2) Berberine is able to suppresse adipogenesis through inhibition of PPARg and C/EBPa function; (3) Berberine
decreases intestinal glucose absorption by inhibition of a-glucosidase; (4) Berberine alleviates diabetic nephropathy and improves islet
function via its antioxidant, aldose reductase and MAPK inhibitory activities; (5) Berberine upregulates LDL receptor (LDLR)
expression through increasing LDLR mRNA, which is related to activation of ERK and JNK pathways.
Jun Yin et al.332insulin level via enhancing insulin sensitivity. However, in
patients with poor b-cell function, berberine may improve
insulin secretion via repairing destructed or exhausted islets.
Compared with other hypoglycemic agents used in clinic,
berberine is of particular interest and may have extra bene-
ﬁcial effects on diabetic cardiovascular complications because
of its cholesterol-lowering property. Berberine is also char-
acterized with the antioxidant and aldose reductase inhibitory
activities, through which berberine alleviates diabetic nephro-
pathy in animals. However, it has not been tested in human
subjects so far. Since evidence-based medicine is the ‘‘gold
standard’’ for clinical practice, large-scale multicenter trials
are needed to evaluate the efﬁcacy of berberine on diabetes
and the related complications.Acknowledgments
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